Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05757570 · ClinicalTrials.gov registry record · Phase 1
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
A Phase 1 study of Immune Thrombocytopenia and Cold Agglutinin Disease, sponsored by Alpine Immune Sciences.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 20
- Study locations
NCT05757570: Active Phase 1 study of Immune Thrombocytopenia and Cold Agglutinin Disease, sponsored by Alpine Immune Sciences.
NCT05757570 is a Phase 1 study of Immune Thrombocytopenia and Cold Agglutinin Disease that is active but no longer recruiting, run by Alpine Immune Sciences. The registered enrollment target is 30 participants, below the 119-participant average among 6 other Immune Thrombocytopenia trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05757570, a Phase 1 study of Immune Thrombocytopenia and Cold Agglutinin Disease, is active but no longer recruiting, sponsored by Alpine Immune Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.
Conditions Studied
Interventions
- DRUG povetacicept
Study Locations (20)
New York
- Investigational site (405) - Lake Success
- Investigational Site (423) - New Hyde Park
- Investigational Site (421) - New York
- Investigational Site (404) - New York
- Investigational Site (420) - Shirley
- Investigational Site (422) - The Bronx
Other
- Investigational Site (410) - Box Hill
- Investigational Site (519) - Concord
- Investigational Site (517) - Douglas
- Investigational Site (413) - Liverpool
- Investigational Site (407) - West Perth
Florida
- Investigational Site (419) - Cooper City
- Investigational Site (425) - Miami
North Carolina
- Investigational Site (414) - Charlotte
- Investigational Site (402) - Greenville
California
- Investigational Site (230) - Los Angeles
District of Columbia
- Investigational Site (401) - Washington D.C.
Iowa
- Investigational Site (219) - Iowa City
Maryland
- Investigational Site (435) - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-07-03 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What the registry record for NCT05757570 still lists
NCT05757570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 119-participant average among 6 other Immune Thrombocytopenia trials with a reported enrollment target (75% lower).
The record links to 4 conditions, with Immune Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which povetacicept is the first listed.
NCT05757570 names 20 study sites across 9 states, led by New York, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT05757570 about?
NCT05757570 is a clinical study titled "An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias". The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment...
What is the current status of trial NCT05757570?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-07-03. Estimated completion is 2026-07.
What conditions does trial NCT05757570 study?
This clinical trial studies the following conditions: Immune Thrombocytopenia, Cold Agglutinin Disease, Idiopathic Thrombocytopenic Purpura, Warm Autoimmune Hemolytic Anemia.
What interventions are being tested in trial NCT05757570?
The interventions under investigation include: povetacicept (DRUG).
Who is sponsoring clinical trial NCT05757570?
This trial is sponsored by Alpine Immune Sciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05757570 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
RECRUITING · Phase 2
-
Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
RECRUITING
-
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
RECRUITING · Phase 3
-
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
COMPLETED · Phase 4
-
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI